Baird Medical Investment Holdings Ltd. develops and commercializes minimally invasive microwave ablation (MWA) medical devices, with a focus on thyroid-related diseases and other soft tissue conditions. News about BDMD commonly covers sales of MWA needles and microwave therapeutic apparatuses, distributor and direct-customer activity, clinical education for physicians, and the company's geographic expansion beyond Mainland China.
Updates also include regulatory clearances in international markets, U.S. clinical-conference engagement, and product-development work tied to software, AI-assisted planning, and robotic surgical systems. Financial releases discuss revenue mix, gross margin, R&D spending, and the effects of market policy and pricing dynamics on the company's China business.
Baird Medical (BDMD) announced additional medical device registrations in Vietnam and preliminary regulatory approval in Egypt for its microwave ablation technology.
Vietnam issued Class C registration certificates for J-series needles for benign thyroid nodules, G-series needles for liver tumors, and MTI-5AT and MTI-5ET generators, following an initial registration in January 2026. Egypt's Drug Authority granted preliminary approval for the BD-GT Microwave Ablation System and related accessories in January 2026, ahead of potential final registration of the system's sterile accessories. The company plans to strengthen U.S. commercial infrastructure and physician engagement following FDA 510(k) clearance in November 2023.
Baird Medical (BDMD) highlighted third-quarter 2026 international expansion, regulatory registrations and a partnership adding another treatment technology to its portfolio.
In August, Pakistan’s Drug Regulatory Authority registered its BD-GT microwave ablation system and T-1610 needle, allowing their introduction in Pakistan. First procedures using its microwave ablation technology were completed in Vietnam and Argentina during the quarter. An August partnership with Alpmed focuses on global development and commercialization of irreversible electroporation, another minimally invasive treatment method. The company plans to continue market expansion, physician training and portfolio development in the fourth quarter.
Baird Medical (BDMD)/b) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City on September 16, 2026, at 11:30 a.m. ET.The presentation, held at the Lotte New York Palace Hotel, will be webcast live via the Investor Relations section of Baird Medical’s website, with a replay available afterward. US CEO Mark Saxton and CSO Daphne Huang will also host one-on-one meetings with institutional investors during the three-day conference.
Baird Medical (BDMD) highlighted its participation at the CIRSE 2026 Annual Congress in Copenhagen, where it engaged with interventional radiologists and showcased its Microwave Ablation (MWA) System.
The congress was held at the Bella Center Copenhagen and brought together healthcare professionals from around the world. Baird Medical presented its MWA System, which is designed for precise and controlled ablation and features temperature control technology, stable 2.45 GHz microwave energy delivery, and a range of specialized probes for different clinical applications. The company said participation in CIRSE supports its global outreach and aligns with its expansion in markets including Pakistan, Vietnam, and Argentina.
Baird Medical (BDMD) reported preliminary unaudited results showing revenue of approximately $9.9 million for the six months ended June 30, 2026, up 24.6% from $8.0 million a year earlier.
Growth was driven mainly by markets outside mainland China, with about two thirds of revenue generated internationally and the United States and Hong Kong as key contributors. Gross profit rose to $8.6 million from $6.5 million, lifting gross margin to 87.0% from 82.1%, helped by geographic and product mix shifts. Total operating expenses dropped to $7.8 million from $17.0 million, as sharply lower research and development and general and administrative costs more than offset higher selling and marketing spend tied to the U.S. commercial ramp.
Net income was $13,499, compared with a net loss of $11.4 million in the prior-year period. EBITDA improved to about $1.6 million from negative $9.7 million, and adjusted EBITDA reached approximately $4.0 million versus negative $3.3 million, reflecting higher gross profit and reduced operating expenses.
Baird Medical (NASDAQ: BDMD) reported that its BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle have received product registrations from the Drug Regulatory Authority of Pakistan (DRAP), strengthening the company’s regulatory base and supporting ongoing commercial activities in Pakistan.
The registrations build on earlier approvals and initial availability at the Armed Forces Institute of Radiology & Imaging in January 2026. Baird Medical highlighted this as part of its broader international expansion, noting first microwave ablation procedures earlier in 2026 by physicians in Vietnam and Argentina.
Baird Medical (NASDAQ: BDMD) and Tianjin Yuanshan Medical Technology, operating as Alpmed, signed a strategic cooperation agreement to form a long-term partnership for global development and commercialization of next-generation irreversible electroporation (IRE) ablation technologies.
The collaboration combines Alpmed's IRE innovation with Baird Medical's clinical, regulatory, and global commercialization capabilities. The partners plan to submit a 510(k) application to the U.S. FDA by the end of 2026 for their first co-developed IRE device, intended for ablation of soft tissue solid tumors in the liver, breast, thyroid, and prostate. According to Baird Medical, it will lead global regulatory approval processes, including in the U.S., and holds worldwide commercialization rights for this IRE product as part of its strategy to expand beyond microwave ablation and build a diversified minimally invasive treatment portfolio.
Baird Medical (NASDAQ: BDMD) announced successful first microwave ablation (MWA) procedures using its technology in Vietnam and Argentina.
The thyroid case in Vietnam and liver ablation in Argentina mark entry into two new markets, supporting Baird Medical's global expansion of minimally invasive treatment options.
Baird Medical (NASDAQ: BDMD) is relocating its global headquarters to New York City, centralizing corporate leadership in the U.S. as part of its global growth strategy in minimally invasive microwave ablation technology.
The move follows the December 2025 appointment of Mark Saxton as CEO of the U.S. subsidiary to lead domestic operations and commercial expansion. The New York headquarters is intended to improve access to U.S. healthcare investors and support a growing national sales force and physician/KOL network, while global operations continue across key healthcare markets.
Baird Medical (NASDAQ: BDMD) reported full year 2025 revenue of $22.5 million, down 39.2% from $37.0 million in 2024, driven mainly by policy-related slowdown in Mainland China. Gross margin was 83.8% and loss from operations was $25.6 million. Total operating expenses rose to $44.5 million, including $17.5 million of one-time share-based compensation. The company named Mark Saxton CEO of Baird U.S. and established a North American production hub with MPS Medical to support U.S. commercial expansion and product advancement.